Firms across various sectors are showing interest in expanding their domestic operations to appease the president. Analysts warn this could lead to higher costs for both consumers and businesses
A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction
European share prices started the year on a positive note, trading at lower valuations, but analysts caution against confirming a trend shift
The one-time treatment is out of reach in India and Africa — places where the disease is most common. Vast inequities cut much of the world off from gene therapy in general
A number of important drugs will lose their exclusivity, paving the way for generics and biosimilars
Drug companies like BMS, GSK and Amgen face revenue losses from patent expirations
The pharmaceutical giant said Monday that it will pay $229 per Seagen share
